These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22771885)

  • 61. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MR imaging helps predict time from symptom onset in patients with acute stroke: implications for patients with unknown onset time.
    Petkova M; Rodrigo S; Lamy C; Oppenheim G; Touzé E; Mas JL; Méder JF; Oppenheim C
    Radiology; 2010 Dec; 257(3):782-92. PubMed ID: 21045177
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
    Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
    Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
    Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
    Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.
    Roques M; Catalaa I; Raveneau M; Attal J; Siegfried A; Darcourt J; Cognard C; de Champfleur NM; Bonneville F
    PLoS One; 2022; 17(10):e0270216. PubMed ID: 36227862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
    Yildirim M; Baykara M
    Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods.
    Jung SC; Choi SH; Yeom JA; Kim JH; Ryoo I; Kim SC; Shin H; Lee AL; Yun TJ; Park CK; Sohn CH; Park SH
    PLoS One; 2013; 8(8):e69323. PubMed ID: 23950891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.
    Surapaneni K; Kennedy BC; Yanagihara TK; DeLaPaz R; Bruce JN
    World Neurosurg; 2015 Jul; 84(1):163-72. PubMed ID: 25772608
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A generic support vector machine model for preoperative glioma survival associations.
    Emblem KE; Pinho MC; Zöllner FG; Due-Tonnessen P; Hald JK; Schad LR; Meling TR; Rapalino O; Bjornerud A
    Radiology; 2015 Apr; 275(1):228-34. PubMed ID: 25486589
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence.
    Blasel S; Zagorcic A; Jurcoane A; Bähr O; Wagner M; Harter PN; Hattingen E
    J Neuroimaging; 2016; 26(1):116-23. PubMed ID: 25907688
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
    Zach L; Guez D; Last D; Daniels D; Grober Y; Nissim O; Hoffmann C; Nass D; Talianski A; Spiegelmann R; Tsarfaty G; Salomon S; Hadani M; Kanner A; Blumenthal DT; Bukstein F; Yalon M; Zauberman J; Roth J; Shoshan Y; Fridman E; Wygoda M; Limon D; Tzuk T; Cohen ZR; Mardor Y
    Neuro Oncol; 2015 Mar; 17(3):457-65. PubMed ID: 25452395
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
    Park JE; Ryu KH; Kim HS; Kim HW; Shim WH; Jung SC; Choi CG; Kim SJ; Kim JH
    PLoS One; 2017; 12(7):e0181933. PubMed ID: 28732091
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
    Alcaide-Leon P; Luks TL; Lafontaine M; Lupo JM; Okada H; Clarke JL; Villanueva-Meyer JE
    J Neurooncol; 2020 Jan; 146(1):71-78. PubMed ID: 31728884
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
    Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
    J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor Heterogeneity in Lung Cancer: Assessment with Dynamic Contrast-enhanced MR Imaging.
    Yoon SH; Park CM; Park SJ; Yoon JH; Hahn S; Goo JM
    Radiology; 2016 Sep; 280(3):940-8. PubMed ID: 27031994
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic Imaging Biomarkers in Glioblastoma: Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images.
    Cui Y; Tha KK; Terasaka S; Yamaguchi S; Wang J; Kudo K; Xing L; Shirato H; Li R
    Radiology; 2016 Feb; 278(2):546-53. PubMed ID: 26348233
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.